Subcutaneous insulin: Pharmacokinetic variability and glycemic variability

Diabetes and Metabolism

Volumn 31, Issue 4 II, 2005, Pages

  Guerci, B ^a   Sauvanet, J P ^b  

^a Ctr Hospitalier Univ de Nancy   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Glycemic control; Glycemic variability; Hypoglycemia; Insulin analogs; Insulin pharmacodynamics; Insulin pharmacokinetics; Insulin therapy regimen; Insulin treated diabetes

Indexed keywords

ADRENALIN; ASPARAGINE; GLUCAGON; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LONG ACTING DRUG; LYSINE; ORAL ANTIDIABETIC AGENT; SHORT ACTING DRUG;

DIABETES MELLITUS; DRUG ABSORPTION; DRUG EFFECT; GLUCOSE HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; LONG TERM CARE; POSTPRANDIAL STATE; REVIEW; SIDE EFFECT; WEIGHT GAIN;

EID: 25644437034     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1262-3636(05)88263-1     Document Type: Review

References (131)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
3. The Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289-98.
4. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997;46:271-86.
5. The Diabetes Control and Complications Trial Research Group. Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care 1995;18: 1415-27.
6. Turner R, Cull C, Holman R, for the United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996;124:136-45.
7. Stratton IM, Adler AI, Neil AW, et al., on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-12.
8. Davies M. The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges. Int J Obes 2004;28 (Suppl. 2): S14-S22.
9. Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988;81:442-8.
10. Scheen AJ. Pathophysiology of insulin secretion. Ann Endocrinol 2004;65:29-36.
11. Service FJ, Hall LD, Westland RE, et al. Effects of size, time of day and sequence of meal ingestion on carbohydrate tolerance in normal subjects. Diabetologia 1983;25:316-21.
12. Kruszynska YT, Home PD, Hanning I, Alberti KGMM. Basal and 24-h C-peptide and insulin secretion in normal man. Diabetologia 1987;30:16-21.
13. Service FJ, Nelson RL. Characteristics of glycemic stability. Diabetes Care 1980;3:58-62.
14. Waldhäusl WK. The physiological basis of insulin treatment. Clinical aspects. Diabetologia 1986;29:837-49.
15. Zinman B. The physiological replacement of insulin: an elusive goal. N Engl J Med 1989;321:363-70.
16. Gin H, Hanaire-Broutin H. Reproducibility and variability in the action of injected insulin. Diabetes Metab 2005;31:7-13.
17. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trial. Br Med J 2002;324:1-6.
18. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy. A meta-analysis. Diabetes Care 2003;26:1079-87.
19. Launtzen T, Prammmg S, Deckert T, Binder C. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 1983;24: 326-9.
20. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984;7:188-99.
21. Christiansen JS, Lauritzen T. Pharmacokinetic aspects of insulin therapy-with special reference to pumps and pens versus conventional insulin treatment. In: "Pharmacology of Diabetes. Present Practice and Future Perspectives". C.E. Mogensen & E. Standl Eds. Walter de Gruyter, Berlin-New York. 1991. pp. 23-38.
22. c and blond glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care 1998;21:977-82.
23. Hanaire-Broutin H, Melki V, Bessières-Lacombe S, Tauber JP. The Study Group for the development of Pump Therapy in Diabetes. Comparison of continuous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment. A randomized study. Diabetes Care 2000;23:1232-5.
24. DeVries JH, Snoek FJ, Kostense PJ, Masurel N, Heine RJ. A randomized trial of continuous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care 2002;25:2074-80.
25. Broussolle C, Jeandidier N, Hanaire-Broutin H. French multicentre experience of implantahle insulin pumps. The EVADIAC Study Group, revaluation of active implants in Diabetes Society. Lancet 1994;343:514-5.
26. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999;42:1151-67.
27. DeWitt DR, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus. Scientific review. JAMA 2003;89:2254-64.
28. Ziel F, Davidson M, Harris MD, Rosenberg CS. The variability in the action of unmodified insulin is more dependent on changes in tissue insulin sensitivity than on insulin absorption. Diabetic Med 1988;5: 662-6.
29. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002;4:673-82.
30. Emdin SO, Dodson GG, Cutfield JM, Cutfield SM. Role of zinc in insulin biosynthesis. Some possible zinc-insulin interactions in the pancreatic β-cell. Diabetologia 1980;19:174-82.
31. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detcmir. Int J Obes 2004;28 (Suppl. 2):S21-S28.
32. Heller S. Reducing hypoglycaemia with insulin analogues. Int J Obes 2002;6 (Suppl. 3):S31-S36.
33. Vaag A, Handberg A, Lauritzen M, Henriksen JE, Pedersen KD, Beck-Nielscn H. Variation in absorption of NPH insulin due to intramuscular injection. Diabetes Care 1990;13:74-6.
34. Koivisto VA, Felig P. Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients. Ann Intern Med 1980;92:59-61.
35. e édition. Technique & Documentation-Lavoisier Ed. Editions Médicales Internationales. Cachan. 1995.499 pages.
36. Ter Braak EW, Woodworth JR, Bianchi R, et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 1996;19:1437-40.
37. Thow J, Home P. Insulin injection technique. Depth of injection is important. Br Med J 1990;01:3-4.
38. Tubiana-Rufi N, Belarbi N, Du Pasquier-Fediacvsky L, et al. Short needles (8 mm) reduce the risk of intramuscular injections in children with type 1 diabetes. Diabetes Care 1999;2:1621-5.
39. Fried A, Linde B. Where do lean diabetics inject their insulin? A study using computed tomography. Br Med J 1986;92:1638.
40. American Diabetes Association. Clinical Practice Recommendations 2004. Insulin administration. Diabetes Care 2004;27 (Suppl. 1):S106-S109.
41. Stewart NL, Darlow BA. Insulin loss at the injection site in children with type 1 diabetes mellitus. Diabetic Med 1994;11:802-5.
42. 125I-labeled insulin glarginc (HOE 901) in healthy men: comparison with NPH insulin and the influence of subcutaneous injection site. Diabetes Care 2000;3:813-9.
43. Jehle PM, Micheler C, Jehle DR, Breitig D, Boehm BO. Inadequate suspension of neutral protamine Hagedom (NPH) insulin in pens. Lancet 1999;354:1604-7.
44. Lepore M, Bartocci L, Fanelli C, Pampanelli S, Porcellati F, Bolli GB. Effect of adequate vs inadequate resuspension of NPH insulin prior to s.c. injection on pharmacokinetics and -dynamics in TIDM. Diabetes 2001;44 (Suppl. 1):A25 [abstract OP92].
45. Rave K, Heise T, Pfützner A, Heinemann L, Sawicki PT. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care 2001;24: 886-90.
46. Brogden RN, Heel RC. Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use. Drugs 1987;34:350-71.
47. Krones R, Heise T, Basir S, Klein C, Kaiser M, Sawicki PT. Time action profiles of insulin aspart and human regular insulin in middle-aged and elderly subjects with type 2 diabetes. Diabetologia 2004;47 (Suppl. 1):A206 [abstract PS735].
48. Sjostrand M, Gudbjornsdottir S, Strindberg L, Lonnroth P. Delayed transcapillary delivery of insulin to muscle interstitial fluid after glucose load in obese subjects. Diabetes 2005;54:152-7.
49. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and II diabetes. Diabetologia, 2002, 45, 937-48.
50. Cryer PE, Davis SN, Shamoon H. Hypoglycaemia in diabetes. Diabetes Care 2003;26:1902-12.
51. Fukuda M, Tanaka A, Tahara Y, et al. Correlation between minimal secretory capacity of pancreatic β-cells and stability of diabetic control. Diabetes 1988;37:81-8.
52. Steffes MW, Sibley S, Jackson M, Thomas W. β-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003;26: 832-6.
53. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes, 2002, 51, 724-33.
54. Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomic failure in insulin dependent diabetes mellitus. J Clin Invest 1993;91:819-28.
55. Tattersall R. Brittle diabetes. Clin Endocr Metab, 1977, 6, 403-19.
56. Selam JL. Comment quantifier l'instabilité glycémique? Diabetes Metab 2000;26:148-51.
57. Gill GV, Lucas S, Kent L. Prevalence and characteristics of brittle diabetes in Britain. Quart J Med 1996;89:839-43.
58. Russell-Jones D. Insulin detemir: improving the predictability of glycaemic control. Int J Obes 2004;28 (Suppl. 2):S29-S34.
59. Galloway JA, Spradlin CT, Nelson RL, Wentworth SM, Davidson JA, Swarner JL. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care 1981;4:366-76.
60. Gerich J, Bolli G, Becker RHA, Zhu R. Fluctuation of serum insulin levels after single and multiple dosing of insulin glargine. Diabetologia 2003;46 (Suppl. 2):A271 [abstract PS783].
61. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49:2142-8.
62. Scholtz HE, van Niekerk N, Meyer BH, Rosenkranz B. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente human insulins using the euglycaemic clamp technique. Diabetologia 1999;42 (Suppl. 1): A235 [abstract 882].
63. Guerci B. Enregistrement de la glycémie en continu: quelles retombées? Ann Endocrinol 2004;65 (Suppl. 1):1S59-1S67.
64. Guerci B. La variabilité glycémique asymptomatique: comment l'évaluer et quelle est son incidence clinique? Diabetes Metab 2003;29: 179-88.
65. Holleman F, Hoekstra JBL. Insulin lispro. N Engl J Med 1997;337: 176-183.
66. Selam JL. Du concept des analogues rapides aux propriétés de l'insuline lispro. Diabetes Metab 1997;23:45-8.
67. Wilde MI, McTavish D. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs 1997;54:597-614.
68. Woodworth JR, Howey DC, Bowsher RR, Lutz S, Santa P, Brady P. [Lys(B28), Pro(B29)] human insulin (K): dose-ranging vs. Humulin R (H). Diabetes 1993;42 (Suppl. 1):54A [abstract 170].
69. Burge MR, Castillo KR, Schade DS. Meal composition is a determinant of lispro-induced hypoglycaemia in IDDM. Diabetes Care 1997; 20:152-5
70. Strachan MW, Frier BM. Optimal time of administration of insulin lispro: importance of meal composition. Diabetes Care 1998;21:26-31.
71. Antsiferov M, Woodworth JR, Mayorov A, Ristic S, Dedov I. Within patient variability in post-prandial glucose excursion with lispro insulin analog compared with regular insulin. Diabetologia 1995;38 (Suppl. 1):A190 [abstract].
72. Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet, 2001, 40, 641-59.
73. Heller S, Kurtzhals P, Verge D, Lindholm A. Insulin aspart: promising early results borne out in clinical practice. Expert Opin Pharmacother 2002;3:183-95.
74. Reynolds N, Wagstaff A. Insulin aspart: a review of its use in the managementof type 1 and 2 diabetes mellitus. Drugs 2004;64:1957-74.
75. Lindholm A, McEwen J, Riis AP. Improved post-prandial glycemic control with insulin aspart. A randomized double blind cross-over trial in type 1 diabetes. Diabetes Care 1999;22:801-5.
76. Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 Asp-Insulin): a fast-acting analog of human insulin. Absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999;22:1501-6.
77. Lyness W, Tyler J, Lawrence A. BMI does not affect aspart pharmacokinetics in type 1 diabetes. Diabetes 2001;50 (Suppl. 2):A124 [abstract 499-P].
78. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 1998;21:1910-4.
79. Becker RHA, Fritz AD, Wessels DH, Scholtz HE. Pharmacodynamics and pharmacokinetics of a new, rapid-acting insulin analog, insulin glulisine. Diabetes 2003;52 (Suppl. 1 ):A110 [abstract 471-P].
80. Kapitza C, Becker RHA, Fritz AD, Heise T, Rave K. Pharmacodynamics and pharmacokinetics of insulin glulisine compared with insulin lispro and regular human insulin in patients with type 2 diabetes. Diabetologia 2004;47 (Suppl. 1):A265 [abstract PS733].
81. Fritz AD, Becker RHA, Wessels DH, Scholtz HE. Pharmacokinetic and glucocodynamic profiles of insulin glulisine following subcutaneous administration at various injection sites. Diabetes 2003;52 (Suppl. 1):A119 [abstract 511-P].
82. McKeage K, Goa KL. Insulin glargine. A review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. Drugs 2001;61:1599-624.
83. Dunn CJ, Plosker GL, Keating GM, McKeage K, Scott LJ. Insulin glargine. An updated review of its use in the management of diabetes mellitus. Drugs 2003;63:1743-78.
84. Gerich JE. Insulin glargine: long-acting basal insulin analog for improved metabolic control. Curr Med Res Opin 2004;20:31-7.
85. Scholtz HE, Becker RHA. Reproducibility of serum insulin and glucose infusion rate profiles of insulin glargine compared with NPH insulin and insulin ultralente. Diabetologia 2004;47 (Suppl. 1):A273 [abstract PS753].
86. Fanelli CG, Pampanelli S, Porcellati F, et al. Pharmacodynamics of subcutaneous injection of insulin glargine after the first as compared to seventh day of its once daily administration in patients with TI DM. Diabetologia 2002;45 (Suppl. 2):A258 [Abstract PS802].
87. Home P. Insulin glargine: the first clinically useful extended-acting insulin in half a century? Exp Opin Invest Drugs 1999;8:307-14.
88. Peter R, Luzio SD, Dunseath G, et al. Effects of exercise on the absorption of insulin glargine in patients with type 1 diabetes. Diabetes Care 2005;28:560-5.
89. Chapman TM, Perry CM. Insulin detemir. A review of its use in the management of type 1 and 2 diabetes melhtus. Drugs 2004;64:2577-95.
90. Brunner GA, Sendlhofer G, Wutte A, et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analog NN304 in comparison to NPH in humans. Exp Clin Endocrinol Diabetes 2000; 108:100-5.
91. Kurtzhals P, Schäffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogemc potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005.
92. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin. A randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001;24:296-301.
93. Pieber TR, Plank J, Görzer E, et al. Duration of action, pharmacodynamic profile and between-subject variability of insulin detemir in subjects with type 1 diabetes. Diabetologia 2002;45 (Suppl. 2):A257 [abstract PS798].
94. Bott S, Tusek C, Jacobsen L, et al. Insulin detemir reaches steady-state after the first day of treatment and shows a peakless time-action profile with twice daily-applications. Diabetologia 2003;46 (Suppl. 2): A271 [abstract PS480].
95. Heise T, Nosek L, Billmann-Ronn B, et al. Lower within subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614-20.
96. Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26:590-6.
97. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bonus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622-9.
98. Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs morning plus bedtime NPH insulin. Diabet Med 2005;22 [in press].
99. Hermansen K, Olsen K, Draeger E, et al. Significant reduction in blood variability with insulin detemir versus NPH insulin: confirmed by meta-analysis of continuous glucose monitoring. Diabetes 2004;53 (Suppl. 2):A104 [abstract 440-P].
100. Owens DR, Zinman B, Bolli GB. Insulin today and beyond. Lancet 2001:358, 739-46.
101. Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Reduction of post-prandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997;46:265-70.
102. Bullano MF, Al-Zakwani IS, Fisher MD, Menditto L, Willey VJ. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on lung-acting and intermediate-acting insulin products. Curr Med Res Opin 2005;21:291-8.
103. Del Pruto S. In search of normoglycaemia in diabetes: controlling post-prandial glucose. Int J Obes 2002;26 (Suppl. 3):S9-S17.
104. Heller S, Kim H, Draeger E. Within-person variation in fasting blood glucose is correlated to incidence of hypoglycaemia in people with type I diabetes treated with insulin dctemir and NPH insulin. Diabetologia 2004;47 (Suppl. 1):A303 [abstract PS841].
105. Charbonnel B, Balarac X, Cazeneuve B, Augendre-Ferrante B, Le Thaï F, Drouin P. Which are the insulin treatment regimens used in France? The "Schema Survey". Diabetes Metab 2001;27:591-7.
106. Cosson E, Elgrahly F, Yalensi P, Slama G, Roger D, Champigneulle A. Modalités d'utilisation des analogues rapides et mixtes de l'insuline par les diabétologues. L'étude ARAMIS. Diabetes Metab 2005;31 (HS 1):1S99 [abstract P201].
107. c and frequency of severe hypoglycemia. An observational cohort study. Diabetes Metab 2003;29:53-7.
108. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes 2002:26 (Suppl. 3):S18-S24.
109. Home PD, Boulton AJM, Jimenez J, et al., on behalf of the Worldwide Initiative for Diabetes Education (WorldWIDE). Issues relating to the early or earlier use of insulin in type 2 diabetes. Pract Diab Int 2003;20:63-71.
110. Ross SA. Controlling diabetes: the need for intensive therapy and barriers in clinical management. Diabetes Res din Pract 2004;65S: S29-S34.
111. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes. Effectiveness, complications, and ressource utilization. JAMA 1997;278:1663-9.
112. Yki-Järvmen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24:758-67.
113. Charbonnel B, Sauvanet JP. Présent et futur de l'insulinothérapie dans le diabète de type 2. Diabetes Metab 2001;27:5S15-5S22.
114. Barnett AH, Capaldi B, Davies-Lyons M, et al. Expert opinion statement on the use of insulin therapy in patients with type 2 diabetes in primary care. Pract Diab Int 2003;20:97-102.
115. Yki-Jarvinen H, Dressler A, Ziemzn M, The HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glarginc compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130-6.
116. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detcmir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005;7:56-64.
117. Riddle MC, Rosenstock J, Gerich J, on behalf of the Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial. Randomized addition of glarginc or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6.
118. Yki-Jarvinen H. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2002;19 (Suppl. 3):S77-S81.
119. Dailey G. Fine-tuning therapy with basal insulin for optimal glycemic control in type 2 diabetes: a review. Curr Med Res Opin 2004;20:2007-14.
120. Rosenstock J. Basal insulin supplementation in type 2 diabetes; refining the tactics. Am J Med 2004;116 (Suppl. 3A):10S-16S.
121. Yki-Jarvinen H. Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue. Eur J Clin Invest 2004;34:410-6.
122. Pritsche A, Haring H. At last, a weight neutral insulin? Int J Obes 2004;28 (Suppl. 2):S41-S46.
123. Penfornis A, Millot L, and the INNOV study group. Initiating insulin treatment in insulin-requiring type 2 diabetic patients: comparative efficiency and cost of outpatient and inpatient management. Diabetes Metab 1998;24:137-42.
124. Müller UA, Müller R, Starrach A, et al. Should insulin therapy in type II diabetic patients be started on an out-or inpatients basis? Results of a prospective controlled trial using the same treatment and teaching programme in ambulatory care and a University hospital. Diabetes Metab 1998;24:251-5.
125. Leralu V, Ketterer JP, Jourdan P, et al. La mise à l'insuline en ambulatoire chez le diabétique de type 2: enquête auprès de 1 215 médecins généralistes de Basse-Normandie. Diabetes Metab 2004;30 (HS1):1S46 [abstract P47].
126. Detournay B, Raccah D, Cadilhac M, Eschwège E. Epidemiology and costs of diabetes treated with insulin in France. Diabetes Metab 2005; 31:2S1-2S18.
127. Fagot-Campagna A, Simon D, Varroud-Vial M, et al. Caracteristiques des personnes diabétiques traitées et adéquation du suivi médical du diabète aux recommandations officielles. Entred 2001. Bull Epidémiol Hehdo 2003;49-50 (n° spécial):238-9.
128. Detournay B, Gros S, Charbonnel B, et al. Managing type 2 diabetes in France: the ECODIA survey. Diabetes Metab 2000;26: 63-9.
129. Charpentier G, Genès L, Vaur L, et al., on behalf of the ESPOIR Diabetes Study Investigators. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey. Diabetes Metab 2003;29:152-8.
130. Varroud-Vial M, Beauduceau B, Attali C, et al. DIASTEP: amélioration de la prise en charge des patients diabétiques de type 2. Etude prospective réalisée par 1 631 médecins généralistes. Diabètes Metab 2003;29 (HS1):1S78 [abstract P142].
131. c goal of 7% in type 2 diabetic patients treated with basal insulin? Results from a nationwide French survey. Diabetologia, 2004;47 (Suppl. 1):A121 [abstract PS318].